...
首页> 外文期刊>AIDS patient care and STDs >Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: Opportunities and challenges
【24h】

Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: Opportunities and challenges

机译:口服暴露前预防(PrEP)在美国预防血清型异性恋夫妇中的HIV:机遇与挑战

获取原文
获取原文并翻译 | 示例
           

摘要

Oral HIV pre-exposure prophylaxis (PrEP) is a promising new biomedical prevention approach in which HIV-negative individuals are provided with daily oral antiretroviral medication for the primary prevention of HIV-1. Several clinical trials have demonstrated efficacy of oral PrEP for HIV prevention among groups at high risk for HIV, with adherence closely associated with level of risk reduction. In the United States (US), three groups have been prioritized for initial implementation of PrEP - injection drug users, men who have sex with men at substantial risk for HIV, and HIV-negative partners within serodiscordant heterosexual couples. Numerous demonstration projects involving PrEP implementation among MSM are underway, but relatively little research has been devoted to study PrEP implementation in HIV-serodiscordant heterosexual couples in the US. Such couples face a unique set of challenges to PrEP implementation at the individual, couple, and provider level with regard to PrEP uptake and maintenance, adherence, safety and toxicity, clinical monitoring, and sexual risk behavior. Oral PrEP also provides new opportunities for serodiscordant couples and healthcare providers for primary prevention and reproductive health. This article provides a review of the critical issues, challenges, and opportunities involved in the implementation of oral PrEP among HIV-serodiscordant heterosexual couples in the US.
机译:口服HIV暴露前预防(PrEP)是一种有前途的新生物医学预防方法,其中,为HIV阴性的个体提供每日口服抗逆转录病毒药物以初步预防HIV-1。几项临床试验表明,口服高剂量的EPEP可以在高HIV感染人群中预防HIV感染,其依从性与降低风险水平密切相关。在美国(美国),优先实施PrEP的三类人群-注射吸毒者,与处于艾滋病毒高风险中的男性发生性行为的男性,以及血清胶结性异性伴侣中的HIV阴性伴侣。 MSM中正在进行许多涉及PrEP实施的示范项目,但是在美国,只有很少的研究专门用于研究HIV血清不一致的异性伴侣中PrEP的实施。在PrEP的摄取和维持,依从性,安全性和毒性,临床监测以及性风险行为方面,此类夫妇在个人,夫妇和提供者一级面临PrEP实施的独特挑战。口服PrEP还为初乳预防夫妇和医疗保健提供者提供了初级预防和生殖健康的新机会。本文回顾了在美国艾滋病毒血清不一致的异性恋夫妇中实施口服PrEP所涉及的关键问题,挑战和机遇。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号